Kai Rejeski, MD
Hematologist and researcher in CAR-T therapy toxicities and hematologic complications, first author of the EBMT/EHA international survey on immune effector cell-associated hematotoxicity and contributor to consensus grading and management recommendations.
Best podcasts with Kai Rejeski, MD
Ranked by the Snipd community
Oct 1, 2025 • 41min
EHA/EBMT Survey on Grading and Management of ICAHT - Dr Kai Rejeski
Dr Kai Rejeski, hematologist researching CAR-T toxicities, discusses prolonged cytopenias after CAR-T and why they were underappreciated. He describes running a 72-center, 18-country survey, debates early GCSF use and stem cell boosts for severe neutropenia. He also talks about creating a practical ICAT grading framework and priorities for future CAR-T research.
Feb 29, 2024 • 13min
Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy
Exploring the importance of lymphodepletion in CAR-T therapy, addressing factors contributing to ICAHT, and discussing the cost effectiveness of CAR-T treatment. Insights from experts on personalized dosing, toxicity reduction, and financial implications of these agents.
